Abstract
Zika virus (ZIKV) is a newly emerged mosquito-borne flavivirus that has been associated with birth defects of babies born to ZIKV-infected mothers. Neutralization activity of serum derived from ZIKV infected and vaccinated individuals is a critical component for characterizing immune response to infection and vaccine efficacy. This protocol describes a modified plaque reduction neutralization 50 (PRNT50) assay that includes an immunostaining step to improve reproducibility and throughput of the assay.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
